ArticleVaccines2019

First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment.

Daria V Vasina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.